Cynthia Schwalm Net Worth
The estimated Net Worth of Cynthia Schwalm is at least $618 Thousand dollars as of 26 December 2018. Ms. Schwalm owns over 1,420 units of G1 Therapeutics stock worth over $33,990 and over the last few years she sold GTHX stock worth over $0. In addition, she makes $583,718 as Independent Director at G1 Therapeutics.
Ms. Schwalm GTHX stock SEC Form 4 insider trading
Cynthia has made over 1 trades of the G1 Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 1,420 units of GTHX stock worth $26,199 on 26 December 2018.
The largest trade she’s ever made was buying 1,420 units of G1 Therapeutics stock on 26 December 2018 worth over $26,199. On average, Cynthia trades about 203 units every 0 days since 2018. As of 26 December 2018 she still owns at least 1,500 units of G1 Therapeutics stock.
You can see the complete history of Ms. Schwalm stock trades at the bottom of the page.
Cynthia Schwalm biography
Cynthia L. Schwalm is Independent Director of the company. She has served as a member of our Board of Directors since June 2018. Starting in 2018, Ms. Schwalm has been an independent consultant and the owner of EIR Advisory LLC, a life science strategic advisory and investment firm. From 2014 to October 2017, Ms. Schwalm served as President and Chief Executive Officer of Ipsen North America. Prior to joining Ipsen, Ms. Schwalm served in senior positions with various biotech and specialty pharmaceutical companies, including as President of Eisai Pharmaceuticals from 2008 to 2010, and at Amgen, Inc. as Vice President & General Manager of U.S. Oncology from 2005 to 2008 and Executive Director of the U.S. Oncology Business Unit from 2003 to 2005. Ms. Schwalm also serves as a director of the Kadmon Group, a publicly traded biopharmaceutical development company, and Caladrius Biosciences, a publicly traded cell therapy development company. Ms. Schwalm also previously held multiple commercial roles at Johnson & Johnson and Janssen Pharmaceutica, Inc. from 1985 to 2003. Ms. Schwalm has held positions on numerous corporate and non-profit boards, including the Women’s Leadership Advisory Board for the John F. Kennedy School of Government at Harvard University and the board of directors for the Sarah Cannon Oncology Research Institute. She currently serves as a Wharton Business School Leadership Advisor. Ms. Schwalm holds an Executive M.B.A. from Wharton School of Business and a B.S. in Nursing from the University of Delaware.
What is the salary of Cynthia Schwalm?
As the Independent Director of G1 Therapeutics, the total compensation of Cynthia Schwalm at G1 Therapeutics is $583,718. There are 7 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.
How old is Cynthia Schwalm?
Cynthia Schwalm is 59, she’s been the Independent Director of G1 Therapeutics since 2018. There are 6 older and 7 younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics, Inc. is Fredric Eshelman, 70, who is the Independent Director.
Insider trading at G1 Therapeutics
Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.
What does G1 Therapeutics do?
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
What does G1 Therapeutics’s logo look like?
Complete history of Ms. Schwalm stock trades at Caladrius Biosciences, G1 Therapeutics, and Kadmon
G1 Therapeutics executives and stock owners
G1 Therapeutics executives and other stock owners filed with the SEC include:
- John Demaree, Chief Commercial Officer
- James Hanson, General Counsel
- Terry Murdock, Chief Operating Officer
- Mark Velleca, President, Chief Executive Officer, Director
- Garry Nicholson, Independent Chairman of the Board
- Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
- Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
- Cynthia Schwalm, Independent Director
- Willie Deese, Independent Director
- Seth Rudnick, Independent Director
- Glenn Muir, Independent Director
- Fredric Eshelman, Independent Director
- Andrew Witty, Independent Director
- Jeff Macdonald, Head of Investor Relations/Public Relations
- Jennifer Moses, Vice President – Finance and Accounting
- Jay Strum, Chief Scientific Officer
- Clay Hatteras Venture Advis…,
- Capital Management, Llcra C…,
- Christy L Shaffer, Director
- Ventures, Inc. Med Immune, 10% owner
- Ventures, Llc Eshelman, 10% owner
- Clay Hatteras Venture Advis…,
- Mark Avagliano, Chief Business Officer